naproxcinod

Phase 3Small molecule

NNicOx

naproxcinod is one of 44 small molecule programs targeting Essential Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

OsteoarthritisActive, not recruiting

Essential HypertensionPhase 1

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

naproxcinod

NNicOx

Phase 3

4 2

Ilaris

Novartis

Preclinical

2 3

Bayer Aspirin

Bayer

Preclinical

—4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Paracetamol

GSK

Preclinical

4 6

Naproxen Sodium

Bayer

Preclinical

1 7

Ansaid

PPharmacia and Upjohn

Benadryl

SGLT2 Inhibitor

1 10

Ozone

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis4 trials

Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

Completed·NNicOx·Phase 3·NCT00542555·918 enrolled

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

Completed·NNicOx·Phase 3·NCT00504127·1,020 enrolled

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

Completed·NNicOx·Phase 1·NCT00662610·120 enrolled

Show 1 more trial

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

Completed·NNicOx·Phase 3·NCT00541489·800 enrolled

Impaired Renal Function1 trial

A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

Completed·NNicOx·Phase 1·NCT00674856·32 enrolled

Essential Hypertension1 trial

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

Completed·NNicOx·Phase 1·NCT00662896·300 enrolled

Oral1 trial

Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male

Completed·NNicOx·Phase 1·NCT01404598·24 enrolled

Phase 11 trial

A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects

Completed·NNicOx·Phase 1·NCT00621881·24 enrolled

1 more indication

Hemodynamic1 trial

Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide

Completed·NNicOx·Phase 1·NCT00909519·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for naproxcinod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — naproxcinod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for naproxcinod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NicOx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNicOx

naproxcinod

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis4 trials

Impaired Renal Function1 trial

Essential Hypertension1 trial

Oral1 trial

Phase 11 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News